| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.076 | 0.09 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.079 | 0.09 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.069 | 0.1 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.059 | 0.2 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.055 | 0.3 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.048 | 0.4 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.037 | 0.4 |